These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9951496)

  • 101. Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression Endpoints.
    Wu Z; Crabb DP; Chauhan BC; Crowston JG; Medeiros FA
    Ophthalmol Glaucoma; 2019; 2(2):72-77. PubMed ID: 32632403
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Two automated perimeters.
    Banfiel R
    J Am Optom Assoc; 1998 Jun; 69(6):347-9; author reply 349-50. PubMed ID: 9646581
    [No Abstract]   [Full Text] [Related]  

  • 103. [Effect of bencyclane on the visual field in glaucoma].
    Szymaniak R; Szczypiński J; Sek B
    Klin Oczna; 1987 Mar; 89(3):100-1. PubMed ID: 3309448
    [No Abstract]   [Full Text] [Related]  

  • 104. Infographic: Collaborative Initial Glaucoma Treatment Study (CIGTS).
    Mohamed A; Han JE; Galiyev Y; Henein C; Mathew RG
    Eye (Lond); 2021 Oct; 35(10):2665-2666. PubMed ID: 33674731
    [No Abstract]   [Full Text] [Related]  

  • 105. Infographic: Advanced Glaucoma Intervention Study (AGIS).
    Hamedani M; Henein C; Mathew RG
    Eye (Lond); 2021 Dec; 35(12):3187-3188. PubMed ID: 33972710
    [No Abstract]   [Full Text] [Related]  

  • 106. Filtering data from the collaborative initial glaucoma treatment study for improved identification of glaucoma progression.
    Schell GJ; Lavieri MS; Stein JD; Musch DC
    BMC Med Inform Decis Mak; 2013 Dec; 13():137. PubMed ID: 24359562
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Improving the Power of Glaucoma Neuroprotection Trials Using Existing Visual Field Data.
    Montesano G; Quigley HA; Crabb DP
    Am J Ophthalmol; 2021 Sep; 229():127-136. PubMed ID: 33905747
    [TBL] [Abstract][Full Text] [Related]  

  • 108. The relationship between progression of visual field defects and retrobulbar circulation in patients with glaucoma.
    Hesse RJ
    Am J Ophthalmol; 1998 Apr; 125(4):566-7. PubMed ID: 9559751
    [No Abstract]   [Full Text] [Related]  

  • 109. Measuring mobility performance: experience gained in designing a mobility course.
    Leat SJ; Lovie-Kitchin JE
    Clin Exp Optom; 2006 Jul; 89(4):215-28. PubMed ID: 16776729
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Glaucoma: fielding progressive disease.
    Viswanathan AC; Hitchings RA
    Eye (Lond); 1998; 12 ( Pt 1)():5-6. PubMed ID: 9614511
    [No Abstract]   [Full Text] [Related]  

  • 111. Practical clinical treatment strategies for evaluation and treatment of visual field loss and visual inattention.
    Berryman A; Rasavage K; Politzer T
    NeuroRehabilitation; 2010; 27(3):261-8. PubMed ID: 21098996
    [No Abstract]   [Full Text] [Related]  

  • 112. [Clinico-statistical study on availability of Esterman disability score for assessment of mobility difficulty in patients with visual field loss].
    Yamagata Y; Terada Y; Suzuki A; Mimura O
    Nippon Ganka Gakkai Zasshi; 2010 Jan; 114(1):14-22. PubMed ID: 20112800
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Visual field in glaucoma.
    Drance SM
    Trans Ophthalmol Soc N Z; 1975; 27():19-21. PubMed ID: 1060215
    [No Abstract]   [Full Text] [Related]  

  • 114. [Visual field abnormality. Diagnostic orientation].
    Mondon H
    Rev Prat; 1992 May; 42(9):1189-92. PubMed ID: 1496251
    [No Abstract]   [Full Text] [Related]  

  • 115. [Proposed scoring system for assessment of functional impairment due to visual field defects].
    Weber J; Schiefer U; Kolling G
    Ophthalmologe; 2004 Oct; 101(10):1030-3. PubMed ID: 15338183
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Artificial neural network analysis of noisy visual field data in glaucoma.
    Henson DB; Spenceley SE; Bull DR
    Artif Intell Med; 1997 Jun; 10(2):99-113. PubMed ID: 9201381
    [TBL] [Abstract][Full Text] [Related]  

  • 117. [Characteristics of glaucomatous visual field regression].
    Katsushima H
    Nippon Ganka Gakkai Zasshi; 1986 Dec; 90(12):1484-9. PubMed ID: 3825777
    [No Abstract]   [Full Text] [Related]  

  • 118. Does the World Health Organization criterion adequately define glaucoma blindness?
    Mokhles P; Schouten J; Beckers H; Webers C
    Clin Ophthalmol; 2017; 11():473-480. PubMed ID: 28280297
    [TBL] [Abstract][Full Text] [Related]  

  • 119. [Therapeutic management of chronic glaucoma at the terminal stage].
    Verin P
    Bull Soc Ophtalmol Fr; 1982 May; 82(5):721-2. PubMed ID: 7127638
    [No Abstract]   [Full Text] [Related]  

  • 120. Visual field progression in glaucoma.
    Heijl A; Bengtsson B; Lindgren G
    Br J Ophthalmol; 1998 Sep; 82(9):1097-8. PubMed ID: 9893615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.